Roivant

Nasdaq: ROIV · SEC EDGAR filings

Results on file1
Average 24h move+18.75%across 1 result with a complete 24h price
1 resultRoivant
Met endpoint

Mosliciguat

Phase 2 n=135 Pulmonary Hypertension

Roivant ROIV

24h stock move +18.75%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.